logo-loader

Motif Bio says two new US patents push exclusivity period over antibiotic out to 2037

Published: 02:40 08 Aug 2018 EDT

petrie dish
The company has a market-ready antibiotic

Motif Bio PLC (LON:MTFB, NASDAQ:MTFB) said the grant of two US patents pushes its exclusivity over antibiotic iclaprim out to 2037.

It follows what’s called a notice of allowance for patents governing the drug’s use to treat bacterial infections, including acute bacterial skin and skin structure infections, hospital-acquired bacterial pneumonia and Staphylococcus aureus lung infections in patients with cystic fibrosis. 

WATCH: Motif Bio secures new patents around optimal dose for iclaprim out to 2037

"These US patents provide additional exclusivity for iclaprim in the treatment of bacterial infections well into 2037,” said chief executive Graham Lumsden. 

“We are actively building our intellectual property portfolio in the U.S. and other key markets around the globe."

Having successfully negotiated two Phase III clinical trials, Motif is gearing up to take its next-generation antibiotic to market.

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

2 hours, 7 minutes ago